Loading…
Krystal Biotech, Inc. is projected to rise to $501.78 by 2027, a +37% move from its current price of $365.81. KRYS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $359.92 | $366.06 | $372.31 | +0.07% |
| Jul 13 | $357.66 | $366.32 | $375.18 | +0.14% |
| Jul 14 | $355.99 | $366.57 | $377.47 | +0.21% |
| Jul 15 | $354.62 | $366.82 | $379.44 | +0.28% |
| Jul 16 | $353.45 | $367.07 | $381.22 | +0.35% |
| Jul 17 | $352.42 | $367.33 | $382.87 | +0.41% |
| Jul 18 | $351.49 | $367.58 | $384.40 | +0.48% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $351.49 | $367.58 | $384.40 | +0.48% |
| Week 2 | $346.71 | $369.36 | $393.49 | +0.97% |
| Week 3 | $343.47 | $371.15 | $401.06 | +1.46% |
| Week 4 | $341.02 | $372.95 | $407.86 | +1.95% |
| Week 5 | $339.07 | $374.75 | $414.19 | +2.44% |
| Week 6 | $337.47 | $376.57 | $420.19 | +2.94% |
| Week 7 | $336.14 | $378.39 | $425.95 | +3.44% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Krystal Biotech, Inc. (KRYS) is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech currently trades at $378.15, with a market cap of $11.15B, and a rank of 840.
The technical picture shows bullish sentiment, with RSI14 at 80, SMA50 at $305.11 and SMA200 at $250.53.
Support is at $291.75 and resistance at $378.15. The 30-day price range spans from $332.28 to $430.36, and annualized volatility is 40.
A major floor 32.9% below — a decisive break under it would weaken the trend.
The nearest floor, 19.8% below — buyers have tended to step in here.
The nearest ceiling, 3.4% above — a clean break opens room to run.
A major ceiling 17.7% above — clearing it would confirm fresh momentum.
Key KRYS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KRYS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $371.15 | Sell | $369.89 | Sell |
| MA 10 | $372.44 | Sell | $366.92 | Sell |
| MA 20 | $354.65 | Buy | $355.07 | Buy |
| MA 50 | $320.96 | Buy | $327.60 | Buy |
| MA 100 | $291.85 | Buy | $301.01 | Buy |
| MA 200 | $259.19 | Buy | $266.63 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.62 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 40.60 | Neutral |
| Williams %R (14) | -32.53 | Info |
| MACD (12,26,9) | -0.83 | Sell |
| ROC (12) | 7.52 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 67.47 | Neutral |
| TRIX (15) | 0.78 | Buy |
| Awesome (5,34) | 37.29 | Buy |
| Ultimate (7,14,28) | 49.24 | Neutral |
| Momentum (10) | 5.88 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 370.11 | Sell |
| ADX (14) | 35.16 | Buy |
| ATR (14) | 5.66 | Info |
The present technical setup signals a bullish stance, with RSI14 at 80 and a bullish sentiment reading. The stock sits above the SMA50 ($305.11) and above the SMA200 ($250.53), suggesting upside momentum. A key near-term level to watch is the resistance at $378.15, with support at $291.75.
Over the last 30 days, Krystal Biotech moved within a range from $332.28 to $430.36, illustrating active price discovery in a tight band around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $244.71 | $365.81 | $508.21 | 0% | Neutral | |
| $410.94 | $501.78 | $640.58 | +37% | Bullish | |
| $450.61 | $560.55 | $734.96 | +53% | Bullish | |
| $542.85 | $685.71 | $918.20 | +87% | Bullish | |
| $615.42 | $787.87 | $1,074.00 | +115% | Bullish | |
| $736.79 | $954.77 | $1,322.08 | +161% | Bullish | |
| $933.77 | $1,223.69 | $1,718.56 | +235% | Bullish | |
| $1,041.13 | $1,378.77 | $1,961.41 | +277% | Bullish | |
| $1,177.70 | $1,575.13 | $2,267.52 | +331% | Bullish | |
| $1,295.84 | $1,749.54 | $2,546.63 | +378% | Bullish | |
| $2,222.09 | $3,129.09 | $4,773.09 | +755% | Bullish | |
| $4,311.38 | $6,511.26 | $10,646.58 | +16.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $244.71 | $365.81 | $432.73 | +0.00% |
| August 2026 | $321.21 | $376.04 | $449.80 | +2.80% |
| September 2026 | $331.18 | $389.57 | $469.60 | +3.60% |
| October 2026 | $332.64 | $392.89 | $476.72 | +0.85% |
| November 2026 | $335.74 | $397.93 | $485.48 | +1.28% |
| December 2026 | $348.56 | $414.45 | $508.21 | +4.15% |
Click any year to see its month-by-month KRYS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The KRYS price prediction for 2026 points to an average of $365.81 (low $244.71, high $508.21) — a potential gain of 0% on today's $365.81. Price action looks broadly range-bound.
In 2027, KRYS is projected to trade between $410.94 and $640.58, averaging $501.78 — a potential gain of +37% from today's $365.81. That is up +37% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Krystal Biotech, Inc.'s 2028 outlook centres on $560.55, within a $450.61 to $734.96 range. That is up +12% on the projected 2027 average. That marks a +53% change versus current levels. Momentum favours further upside here.
By 2029, KRYS could reach as high as $918.20, with a base case around $685.71 and support toward $542.85 — roughly +87% from $365.81. Buyers look set to stay in control over this stretch.
Expect KRYS to range from $615.42 to $1,074.00 through 2030. The $787.87 average target implies a +115% move from current prices. That is up +15% on the projected 2029 average. Momentum favours further upside here.
The KRYS price prediction for 2031 points to an average of $954.77 (low $736.79, high $1,322.08) — a potential gain of +161% on today's $365.81. Buyers look set to stay in control over this stretch.
In 2032, KRYS is projected to trade between $933.77 and $1,718.56, averaging $1,223.69 — a potential gain of +235% from today's $365.81. That is up +28% on the projected 2031 average. Momentum favours further upside here.
Krystal Biotech, Inc.'s 2033 outlook centres on $1,378.77, within a $1,041.13 to $1,961.41 range. That is up +13% on the projected 2032 average. That marks a +277% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, KRYS could reach as high as $2,267.52, with a base case around $1,575.13 and support toward $1,177.70 — roughly +331% from $365.81. Momentum favours further upside here.
Expect KRYS to range from $1,295.84 to $2,546.63 through 2035. The $1,749.54 average target implies a +378% move from current prices. That is up +11% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The KRYS price prediction for 2040 points to an average of $3,129.09 (low $2,222.09, high $4,773.09) — a potential gain of +755% on today's $365.81. Momentum favours further upside here.
In 2050, KRYS is projected to trade between $4,311.38 and $10,646.58, averaging $6,511.26 — a potential gain of +16.8x from today's $365.81. That is up +108% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in KRYS today (≈ 2.73366 KRYS) could be worth
$17,799.57
+$16,799.57 (+1680%) by 2050 · US Dollar
Based on the average projected KRYS price of $6,511.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KRYSwould be worth at today's price.
$1,000 invested in KRYS on Jul 10, 2025 (≈ 6.678242 KRYS) would be worth
$2,442.97
+$1,442.97 (+144.3%) today · 2.44× · US Dollar
Based on a KRYS entry price of $149.74 vs. today's $365.81.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $375.07 | $975.31 | -2.5% |
| 1 month ago | $312.41 | $1,170.93 | +17.1% |
| 3 months ago | $259 | $1,412.39 | +41.2% |
| 6 months ago | $272.13 | $1,344.25 | +34.4% |
| 1 year ago | $149.74 | $2,442.97 | +144.3% |
| All time (5.0y) ago | $68.33 | $5,353.58 | +435.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KRYS forecast.
Our base-case forecast reaches $730.00 around 2030.
Implied market cap at $730.00: $21.52B
The forecast shows a multi-year bullish trajectory with a transition from Neutral in 2026 to Bullish thereafter. The 2026 min $244.71, avg $378.15, max $531.39, ROI 0, sentiment NEUTRAL; 2027 min $416.32, avg $509.99, max $654.15, ROI 34.9, sentiment BULLISH; 2028 min $454.78, avg $567.95, max $748.74, ROI 50.2, sentiment BULLISH; 2029 min $546.81, avg $693.85, max $934.77, ROI 83.5, sentiment BULLISH.
For 2030 the min is $607.55, avg $781.77, max $1,072.77, ROI 106.7, sentiment BULLISH; 2031 min $724.35, avg $943.95, max $1,316.44, ROI 149.6, sentiment BULLISH; 2032 min $915.73, avg $1,207.43, max $1,708.59, ROI 219.3, sentiment BULLISH; 2033 min $1,004.17, avg $1,338.63, max $1,919.53, ROI 254, sentiment BULLISH; 2034 min $1,139.74, avg $1,535.17, max $2,228.47, ROI 306, sentiment BULLISH; 2035 min $1,249.36, avg $1,699.51, max $2,495.33, ROI 349.4, sentiment BULLISH.
The long horizon continues with 2040 min $2,094.63, avg $2,977.93, max $4,588.51, ROI 687.5, sentiment BULLISH; and 2050 min $3,982.48, avg $6,094.57, max $10,086.36, ROI 1511.7, sentiment BULLISH. These figures illustrate a steadily rising path with substantial upside potential, while remaining contingent on future factors and recognizing the estimates are not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows min $607.55, avg $781.77, max $1,072.77 with ROI 106.7% and sentiment BULLISH.
The forecast transitions from neutral in 2026 to bullish from 2027 onward, with rising average prices and positive ROIs (e.g., 2027 ROI 34.9%, 2030 ROI 106.7%, 2050 ROI 1511.7%). These are estimates and not guarantees.
Yes. The 2030 max is $1,072.77, which surpasses $1,000, and higher maxima appear in later years (e.g., 2033 max $1,919.53, 2040 max $4,588.51, 2050 max $10,086.36).
Current price is $378.15 and market cap is $11.15B. The rank is 840.
The sentiment is BULLISH with RSI14 at 80. The SMA50 is $305.11 and the SMA200 is $250.53, with support at $291.75 and resistance at $378.15. The 30-day range is $332.28 to $430.36, and annualized volatility is 40.
Krystal Biotech, Inc. Community Discussion
0Share your Krystal Biotech, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.